REGNRegeneron Pharmaceuticals
$746.46+25% 1Y
$746.46
$553.3252 weeks$852.16
REGN in its own filings
Nothing in REGN's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
542
Events found in the filings · across 2,469 filings · the record starts in 1995
- Hard flags
- none
Hard flags
- Most recent filing
- Oct 6, 2026
Most recent filing · Form 8-K
- Record starts
- Jul 26, 1995
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Jan 11, 2027
- SEC comment-letter activity45 occurrences
- 2025-04-17
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 6, 2026On October 1, 2026, Regeneron Pharmaceuticals, Inc., a New York corporation (“Regeneron” or the “Company”), Sanofi Biotechnology SAS, a société par actions simplifée organized under the laws of France (“Sanofi Biotechnology”), and Sanofi, a société anonyme organized under the laws of France (“Sanofi Parent” and, with …Material agreement entered · Form 8-K
- Sep 30, 2026New Equity Awards for CEO and CSO Effective September 24, 2026 (the “Grant Date”), the Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) granted, upon the approval of the independent, non-employee members of …Director or officer change · Form 8-K
- Jul 30, 2026Regeneron Reports Second Quarter 2026 Financial and Operating Results.Earnings release · press release
- Apr 29, 2026Regeneron Reports First Quarter 2026 Financial and Operating Results.Earnings release · press release
- Jan 30, 2026Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results.Earnings release · press release
- Jan 12, 2026This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially.Earnings release · press release
- Oct 28, 2025Regeneron Reports Third Quarter 2025 Financial and Operating Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Biotechnology
The closest names by size in the same industry